Last 12 months
Inside the activity.
0 purchase rows · 4 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 2 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 31, 2019 Filed Jan 3, 2020 23:50 UTC |
LACY ALAN JDirector
|
GrantDeferred Share Units · Derivative | 477.099 | $64.19 | $30,624.98 |
DisclosureSEC source: 0000014272-20-000020 · wf-form4_157809539470580.xml · derivative · entry 1 LACY ALAN J · CIK 0001200232 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,030.666 Underlying: Common Stock, $0.10 par value · 477.099 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 23:50 UTC |
Paliwal Dinesh CDirector
|
GrantDeferred Share Units · Derivative | 574.466 | $64.19 | $36,874.97 |
DisclosureSEC source: 0000014272-20-000021 · wf-form4_157809541689933.xml · derivative · entry 1 Paliwal Dinesh C · CIK 0001360224 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,906.843 Underlying: Common Stock, $0.10 par value · 574.466 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 23:50 UTC |
Samuels Theodore R. IIDirector
|
GrantDeferred Share Units · Derivative | 477.099 | $64.19 | $30,624.98 |
DisclosureSEC source: 0000014272-20-000022 · wf-form4_157809543970791.xml · derivative · entry 1 Samuels Theodore R. II · CIK 0001688276 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,640.1 Underlying: Common Stock, $0.10 par value · 477.099 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 23:51 UTC |
Storch Gerald LDirector
|
GrantDeferred Share Units · Derivative | 506.309 | $64.19 | $32,499.97 |
DisclosureSEC source: 0000014272-20-000023 · wf-form4_157809546030752.xml · derivative · entry 1 Storch Gerald L · CIK 0001205004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,630.178 Underlying: Common Stock, $0.10 par value · 506.309 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 23:51 UTC |
Vousden Karen HDirector
|
GrantDeferred Share Units · Derivative | 603.677 | $64.19 | $38,750.03 |
DisclosureSEC source: 0000014272-20-000024 · wf-form4_157809548218982.xml · derivative · entry 1 Vousden Karen H · CIK 0001723884 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,542.74 Underlying: Common Stock, $0.10 par value · 603.677 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 23:52 UTC |
YALE PHYLLIS RDirector
|
GrantDeferred Share Units · Derivative | 177.802 | $64.19 | $11,413.11 |
DisclosureSEC source: 0000014272-20-000025 · wf-form4_157809550341332.xml · derivative · entry 1 YALE PHYLLIS R · CIK 0001269070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 833.715 Underlying: Common Stock, $0.10 par value · 177.802 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| December 31, 2019 Filed Jan 4, 2020 00:00 UTC |
Vessey RupertPres., Research & Early Dev.
|
Exercise / conversionRestricted Stock Units · Derivative | 16,060 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-20-000029 · wf-form4_157809602702986.xml · derivative · entry 4 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 16,060 shares Expires 2019-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F2 · shares: The restricted stock unit vests in full on December 31, 2019, which is the end of the original performance period associated with the original Performance Share Unit award. F2 · derivative.exercise_date: The restricted stock unit vests in full on December 31, 2019, which is the end of the original performance period associated with the original Performance Share Unit award. F2 · derivative.expiration_date: The restricted stock unit vests in full on December 31, 2019, which is the end of the original performance period associated with the original Performance Share Unit award. Read SEC document |
| December 31, 2019 Filed Jan 4, 2020 00:00 UTC |
Vessey RupertPres., Research & Early Dev.
|
Tax withholdingCommon Stock, $0.10 par value | 7,910 | $64.19 | $507,742.90 |
DisclosureSEC source: 0000014272-20-000029 · wf-form4_157809602702986.xml · nonDerivative · entry 2 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,868 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| December 31, 2019 Filed Jan 4, 2020 00:00 UTC |
Vessey RupertPres., Research & Early Dev.
|
Exercise / conversionCommon Stock, $0.10 par value | 16,060 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-20-000029 · wf-form4_157809602702986.xml · nonDerivative · entry 1 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,778 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: In connection with the merger, all outstanding Celgene Corporation (Celgene) performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time),multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement,and (B) the right to receive, immediately upon,and subject to, the vesting of such equity award, one CVR per share underlying each such equity award. F2 · shares: The restricted stock unit vests in full on December 31, 2019, which is the end of the original performance period associated with the original Performance Share Unit award. Read SEC document |
| December 31, 2019 Filed Jan 4, 2020 00:00 UTC |
Elkins David VEVP, Chief Financial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 12,373 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-20-000028 · wf-form4_157809600587903.xml · derivative · entry 4 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 12,373 shares Expires 2019-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F2 · shares: The restricted stock unit vests in full on December 31, 2019, which is the end of the original performance period associated with the original Performance Share Unit award. F2 · derivative.exercise_date: The restricted stock unit vests in full on December 31, 2019, which is the end of the original performance period associated with the original Performance Share Unit award. F2 · derivative.expiration_date: The restricted stock unit vests in full on December 31, 2019, which is the end of the original performance period associated with the original Performance Share Unit award. Read SEC document |
| December 31, 2019 Filed Jan 4, 2020 00:00 UTC |
Elkins David VEVP, Chief Financial Officer
|
Tax withholdingCommon Stock, $0.10 par value | 6,094 | $64.19 | $391,173.86 |
DisclosureSEC source: 0000014272-20-000028 · wf-form4_157809600587903.xml · nonDerivative · entry 2 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,187 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| December 31, 2019 Filed Jan 4, 2020 00:00 UTC |
Elkins David VEVP, Chief Financial Officer
|
Exercise / conversionCommon Stock, $0.10 par value | 12,373 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-20-000028 · wf-form4_157809600587903.xml · nonDerivative · entry 1 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,281 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: In connection with the merger, all outstanding Celgene Corporation (Celgene) performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time),multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement,and (B) the right to receive, immediately upon,and subject to, the vesting of such equity award, one CVR per share underlying each such equity award. F2 · shares: The restricted stock unit vests in full on December 31, 2019, which is the end of the original performance period associated with the original Performance Share Unit award. Read SEC document |
| December 31, 2019 Filed Jan 15, 2020 22:04 UTC Amendment |
Vessey RupertPres., Research & Early Dev.
|
Tax withholdingCommon Stock, $0.10 par value | 7,910 | $64.19 | $507,742.90 |
DisclosureSEC source: 0000014272-20-000040 · wf-form4a_157912585811970.xml · nonDerivative · entry 2 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,328 F4 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| December 31, 2019 Filed Jan 15, 2020 22:04 UTC Amendment |
Vessey RupertPres., Research & Early Dev.
|
Exercise / conversionCommon Stock, $0.10 par value | 16,060 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-20-000040 · wf-form4a_157912585811970.xml · nonDerivative · entry 1 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,238 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: In connection with the merger, all outstanding Celgene Corporation (Celgene) performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time),multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement,and (B) the right to receive, immediately upon,and subject to, the vesting of such equity award, one CVR per share underlying each such equity award. F2 · shares: The restricted stock unit vests in full on December 31, 2019, which is the end of the original performance period associated with the original Performance Share Unit award. F3 · balance_after: Due to an administrative error, this Form 4 is being amended to report in Column 5 the correct number of securities beneficially owned following the reported transaction. Read SEC document |
| December 11, 2019 Filed Jan 17, 2020 22:40 UTC |
Bancroft Charles AEVP, Head of Integration
|
GiftCommon Stock, $0.10 par value | 3,685 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-20-000043 · wf-form5_157930083419220.xml · nonDerivative · entry 1 Bancroft Charles A · CIK 0001480250 · EVP, Head of Integration 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 392,309.283 F1 · shares: This transaction involved a transfer of securities by the Reporting Person to a charitable donor advised fund. Read SEC document |
| December 05, 2019 Filed Dec 9, 2019 21:44 UTC |
Dubow AdamChief Compliance & Ethics Offi
|
SaleCommon Stock, $0.10 par value | 1,740 | $58.81 | $102,329.40 |
DisclosureSEC source: 0000014272-19-000243 · wf-form4_157592780983675.xml · nonDerivative · entry 1 Dubow Adam · CIK 0001744507 · Chief Compliance & Ethics Offi 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,749.152 Read SEC document |
| December 04, 2019 Filed Jun 9, 2020 23:16 UTC |
BONNEY MICHAEL WDirector
|
PurchaseCommon Stock, $0.10 par value | 88 | $58.90 | $5,183.20 |
DisclosureSEC source: 0000014272-20-000183 · wf-form4_159174456763815.xml · nonDerivative · entry 1 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,189 F1 · date: Due to an administrative error, this Form 4 was not timely filed. F2 · balance_after: Reflects the current total of securities beneficially owned by the reporting person, including the reported transaction. Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 21:58 UTC |
AHMED NADIMPresident, Hematology
|
GrantRestricted Stock Units · Derivative | 26,376 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-19-000238 · wf-form4_157549668296245.xml · derivative · entry 1 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,376 Underlying: Common Stock, $0.10 par value · 26,376 shares Expires 2023-12-02 F1 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on December 2, 2020. F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on December 2, 2020. Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 21:58 UTC |
BOERNER CHRISTOPHER S.EVP, Chief Commercial Officer
|
GrantRestricted Stock Units · Derivative | 10,550 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-19-000239 · wf-form4_157549670465788.xml · derivative · entry 1 BOERNER CHRISTOPHER S. · CIK 0001543747 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,550 Underlying: Common Stock, $0.10 par value · 10,550 shares Expires 2023-12-02 F1 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on December 2, 2020. F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on December 2, 2020. Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 21:59 UTC |
Elkins David VEVP, Chief Financial Officer
|
GrantRestricted Stock Units · Derivative | 35,168 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-19-000240 · wf-form4_157549673340772.xml · derivative · entry 1 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,168 Underlying: Common Stock, $0.10 par value · 35,168 shares Expires 2023-12-02 F1 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on December 2, 2020. F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on December 2, 2020. Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 21:59 UTC |
Vessey RupertPres., Research & Early Dev.
|
GrantRestricted Stock Units · Derivative | 35,168 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-19-000241 · wf-form4_157549675679272.xml · derivative · entry 1 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,168 Underlying: Common Stock, $0.10 par value · 35,168 shares Expires 2023-12-02 F1 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on December 2, 2020. F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on December 2, 2020. Read SEC document |
| December 01, 2019 Filed Dec 3, 2019 22:28 UTC |
Eid JosephSVPHead Global Medical Affairs
|
Exercise / conversionRestricted Stock Units · Derivative | 2,825 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-19-000233 · wf-form4_157541211408099.xml · derivative · entry 3 Eid Joseph · CIK 0001780247 · SVPHead Global Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,651 Underlying: Common Stock, $0.10 par value · 2,825 shares Expires 2021-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit coverts into one share of common stock upon vesting. F1 · shares: The restricted stock unit vests in four equal annual installments beginning on December 1, 2018. F1 · derivative.exercise_date: The restricted stock unit vests in four equal annual installments beginning on December 1, 2018. F1 · derivative.expiration_date: The restricted stock unit vests in four equal annual installments beginning on December 1, 2018. Read SEC document |
| December 01, 2019 Filed Dec 3, 2019 22:28 UTC |
Eid JosephSVPHead Global Medical Affairs
|
Tax withholdingCommon Stock, $0.10 par value | 968 | $56.94 | $55,117.92 |
DisclosureSEC source: 0000014272-19-000233 · wf-form4_157541211408099.xml · nonDerivative · entry 2 Eid Joseph · CIK 0001780247 · SVPHead Global Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,027 F2 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| December 01, 2019 Filed Dec 3, 2019 22:28 UTC |
Eid JosephSVPHead Global Medical Affairs
|
Exercise / conversionCommon Stock, $0.10 par value | 2,825 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-19-000233 · wf-form4_157541211408099.xml · nonDerivative · entry 1 Eid Joseph · CIK 0001780247 · SVPHead Global Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,995 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The restricted stock unit vests in four equal annual installments beginning on December 1, 2018. Read SEC document |
| December 01, 2019 Filed Mar 12, 2020 22:13 UTC Amendment |
Eid JosephSVP,Head Glob. Medical Affairs
|
Exercise / conversionRestricted Stock Units · Derivative | 2,825 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-20-000117 · wf-form4a_158405117849751.xml · derivative · entry 3 Eid Joseph · CIK 0001780247 · SVP,Head Glob. Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,651 Underlying: Common Stock, $0.10 par value · 2,825 shares Expires 2021-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit coverts into one share of common stock upon vesting. F1 · shares: The restricted stock unit vests in four equal annual installments beginning on December 1, 2018. F1 · derivative.exercise_date: The restricted stock unit vests in four equal annual installments beginning on December 1, 2018. F1 · derivative.expiration_date: The restricted stock unit vests in four equal annual installments beginning on December 1, 2018. Read SEC document |
| December 01, 2019 Filed Mar 12, 2020 22:13 UTC Amendment |
Eid JosephSVP,Head Glob. Medical Affairs
|
Tax withholdingCommon Stock, $0.10 par value | 968 | $56.94 | $55,117.92 |
DisclosureSEC source: 0000014272-20-000117 · wf-form4a_158405117849751.xml · nonDerivative · entry 2 Eid Joseph · CIK 0001780247 · SVP,Head Glob. Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,327 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| December 01, 2019 Filed Mar 12, 2020 22:13 UTC Amendment |
Eid JosephSVP,Head Glob. Medical Affairs
|
Exercise / conversionCommon Stock, $0.10 par value | 2,825 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-20-000117 · wf-form4a_158405117849751.xml · nonDerivative · entry 1 Eid Joseph · CIK 0001780247 · SVP,Head Glob. Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,295 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The restricted stock unit vests in four equal annual installments beginning on December 1, 2018. F2 · balance_after: Due to an administrative error, 1,300 shares were inadvertently omitted from the Form 4 filed on December 3, 2019. This amendment is being filed to include such shares. All other information set forth in the December 3, 2019 Form 4 remains correct. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 21:57 UTC |
YALE PHYLLIS RDirector
|
GrantDeferred Share Units · Derivative | 655.913 | $56.41 | $37,000.05 |
DisclosureSEC source: 0000014272-19-000203 · wf-form4_157445984874010.xml · derivative · entry 1 YALE PHYLLIS R · CIK 0001269070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 655.913 Underlying: Common Stock, $0.10 par value · 655.913 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · shares: Represents pro rata portion of the 2019 annual Deferred Share Units awards granted to the Company's directors. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 21:59 UTC |
BONNEY MICHAEL WDirector
|
GrantDeferred Share Units · Derivative | 655.913 | $56.41 | $37,000.05 |
DisclosureSEC source: 0000014272-19-000204 · wf-form4_157445995567267.xml · derivative · entry 1 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 655.913 Underlying: Common Stock, $0.10 par value · 655.913 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · shares: Represents pro rata portion of the 2019 annual Deferred Share Units awards granted to the Company's directors. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 22:00 UTC |
Haller Julia ADirector
|
GrantDeferred Share Units · Derivative | 655.913 | $56.41 | $37,000.05 |
DisclosureSEC source: 0000014272-19-000205 · wf-form4_157446000139234.xml · derivative · entry 1 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 655.913 Underlying: Common Stock, $0.10 par value · 655.913 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · shares: Represents pro rata portion of the 2019 annual Deferred Share Units awards granted to the Company's directors. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. Read SEC document |
| November 20, 2019 Filed Nov 27, 2019 22:31 UTC |
AHMED NADIMPresident, Hematology
|
GrantRestricted Stock Units · Derivative | 2,908 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 32 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,908 Underlying: Common Stock, $0.10 par value · 2,908 shares Expires 2020-05-01 F5 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F6 · derivative.exercise_price: The restricted stock unit vests in three equal annual installments beginning on May 1, 2018. F5 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting. F6 · derivative.exercise_date: The restricted stock unit vests in three equal annual installments beginning on May 1, 2018. Read SEC document |
| November 20, 2019 Filed Nov 27, 2019 22:31 UTC |
AHMED NADIMPresident, Hematology
|
GrantOption (right to buy) · Derivative | 19,621 | $0.00 Strike: $38.41 | $0.00 |
DisclosureSEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 31 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,621 Underlying: Common Stock, $0.10 par value · 19,621 shares Expires 2028-10-29 F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 27, 2019 22:31 UTC |
AHMED NADIMPresident, Hematology
|
GrantOption (right to buy) · Derivative | 19,619 | $0.00 Strike: $47.81 | $0.00 |
DisclosureSEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 30 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,619 Underlying: Common Stock, $0.10 par value · 19,619 shares Expires 2028-07-30 F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 27, 2019 22:31 UTC |
AHMED NADIMPresident, Hematology
|
GrantOption (right to buy) · Derivative | 19,619 | $0.00 Strike: $44.70 | $0.00 |
DisclosureSEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 29 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,619 Underlying: Common Stock, $0.10 par value · 19,619 shares Expires 2028-05-08 F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 27, 2019 22:31 UTC |
AHMED NADIMPresident, Hematology
|
GrantOption (right to buy) · Derivative | 9,299 | $0.00 Strike: $55.52 | $0.00 |
DisclosureSEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 28 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,299 Underlying: Common Stock, $0.10 par value · 9,299 shares Expires 2028-01-29 F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 27, 2019 22:31 UTC |
AHMED NADIMPresident, Hematology
|
GrantOption (right to buy) · Derivative | 9,300 | $0.00 Strike: $54.29 | $0.00 |
DisclosureSEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 27 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,300 Underlying: Common Stock, $0.10 par value · 9,300 shares Expires 2027-10-30 F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 27, 2019 22:31 UTC |
AHMED NADIMPresident, Hematology
|
GrantOption (right to buy) · Derivative | 5,843 | $0.00 Strike: $72.42 | $0.00 |
DisclosureSEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 26 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,843 Underlying: Common Stock, $0.10 par value · 5,843 shares Expires 2027-07-31 F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 27, 2019 22:31 UTC |
AHMED NADIMPresident, Hematology
|
GrantOption (right to buy) · Derivative | 5,843 | $0.00 Strike: $66.35 | $0.00 |
DisclosureSEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 25 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,843 Underlying: Common Stock, $0.10 par value · 5,843 shares Expires 2027-05-01 F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 27, 2019 22:31 UTC |
AHMED NADIMPresident, Hematology
|
GrantOption (right to buy) · Derivative | 12,272 | $0.00 Strike: $60.53 | $0.00 |
DisclosureSEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 24 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,272 Underlying: Common Stock, $0.10 par value · 12,272 shares Expires 2027-01-30 F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 27, 2019 22:31 UTC |
AHMED NADIMPresident, Hematology
|
GrantOption (right to buy) · Derivative | 12,205 | $0.00 Strike: $54.94 | $0.00 |
DisclosureSEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 23 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,205 Underlying: Common Stock, $0.10 par value · 12,205 shares Expires 2026-10-31 F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 27, 2019 22:31 UTC |
AHMED NADIMPresident, Hematology
|
GrantOption (right to buy) · Derivative | 5,843 | $0.00 Strike: $61.34 | $0.00 |
DisclosureSEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 22 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,843 Underlying: Common Stock, $0.10 par value · 5,843 shares Expires 2026-08-01 F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 27, 2019 22:31 UTC |
AHMED NADIMPresident, Hematology
|
GrantOption (right to buy) · Derivative | 5,812 | $0.00 Strike: $56.44 | $0.00 |
DisclosureSEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 21 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,812 Underlying: Common Stock, $0.10 par value · 5,812 shares Expires 2026-05-02 F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 27, 2019 22:31 UTC |
AHMED NADIMPresident, Hematology
|
GrantOption (right to buy) · Derivative | 9,299 | $0.00 Strike: $54.20 | $0.00 |
DisclosureSEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 20 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,299 Underlying: Common Stock, $0.10 par value · 9,299 shares Expires 2026-02-01 F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 27, 2019 22:31 UTC |
AHMED NADIMPresident, Hematology
|
GrantOption (right to buy) · Derivative | 9,350 | $0.00 Strike: $61.01 | $0.00 |
DisclosureSEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 19 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,350 Underlying: Common Stock, $0.10 par value · 9,350 shares Expires 2025-11-09 F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 27, 2019 22:31 UTC |
AHMED NADIMPresident, Hematology
|
GrantOption (right to buy) · Derivative | 9,350 | $0.00 Strike: $70.89 | $0.00 |
DisclosureSEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 18 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,350 Underlying: Common Stock, $0.10 par value · 9,350 shares Expires 2025-07-27 F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 27, 2019 22:31 UTC |
AHMED NADIMPresident, Hematology
|
GrantOption (right to buy) · Derivative | 9,350 | $0.00 Strike: $58.78 | $0.00 |
DisclosureSEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 17 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,350 Underlying: Common Stock, $0.10 par value · 9,350 shares Expires 2025-05-04 F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 27, 2019 22:31 UTC |
AHMED NADIMPresident, Hematology
|
GrantOption (right to buy) · Derivative | 7,012 | $0.00 Strike: $63.41 | $0.00 |
DisclosureSEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 16 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,012 Underlying: Common Stock, $0.10 par value · 7,012 shares Expires 2025-02-02 F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 27, 2019 22:31 UTC |
AHMED NADIMPresident, Hematology
|
GrantOption (right to buy) · Derivative | 9,350 | $0.00 Strike: $62.67 | $0.00 |
DisclosureSEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 15 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,350 Underlying: Common Stock, $0.10 par value · 9,350 shares Expires 2024-12-19 F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 27, 2019 22:31 UTC |
AHMED NADIMPresident, Hematology
|
GrantOption (right to buy) · Derivative | 6,975 | $0.00 Strike: $55.44 | $0.00 |
DisclosureSEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 14 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,975 Underlying: Common Stock, $0.10 par value · 6,975 shares Expires 2024-10-27 F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 27, 2019 22:31 UTC |
AHMED NADIMPresident, Hematology
|
GrantOption (right to buy) · Derivative | 13,949 | $0.00 Strike: $47.12 | $0.00 |
DisclosureSEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 13 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,949 Underlying: Common Stock, $0.10 par value · 13,949 shares Expires 2024-07-28 F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.